Melanoma is one of the
cancers of fastest-rising incidence in the world.
Inducible nitric oxide synthase (iNOS) is overexpressed in
melanoma and other
cancers, and previous data suggest that iNOS and
nitric oxide (NO) drive survival and proliferation of human
melanoma cells. However, specific mechanisms through which this occurs are poorly defined. One candidate is the PI3K-AKT-mTOR pathway, which plays a major role in proliferation, angiogenesis, and
metastasis of
melanoma and other
cancers. We used the chick embryo chorioallantoic membrane (CAM) assay to test the hypothesis that
melanoma growth is regulated by iNOS-dependent mTOR pathway activation. Both pharmacologic inhibition and
siRNA-mediated gene silencing of iNOS suppressed
melanoma proliferation and in vivo growth on the CAM in human
melanoma models. This was associated with strong downregulation of mTOR pathway activation by Western blot analysis of p-mTOR, p70 ribosomal
S6 kinase (p-P70S6K), p-S6RP, and p-4EBP1. iNOS expression and NO were associated with reversible nitrosylation of
tuberous sclerosis complex (
TSC) 2, and inhibited dimerization of TSC2 with its inhibitory partner TSC1, enhancing
GTPase activity of its target Ras homolog enriched in brain (Rheb), a critical activator of mTOR signaling. Immunohistochemical analysis of
tumor specimens from stage III
melanoma patients showed a significant correlation between iNOS expression levels and expression of the mTOR pathway members. Exogenously supplied NO was also sufficient to reverse the mTOR pathway inhibition by the B-Raf inhibitor
vemurafenib. In summary, covalent modification of TSC2 by iNOS-derived NO is associated with impaired TSC2/TSC1 dimerization, mTOR pathway activation, and proliferation of human
melanoma. This model is consistent with the known association of iNOS overexpression and poor prognosis in
melanoma and other
cancers.